You are here
Recent Pfizer Press Releases
Pfizer Inc. (NYSE:PFE) today announced that it has received . . .
more...
Data to be Presented on More Than 15 Clinical-Stage Assets in Both Solid and Hematologic Tumors
Pfizer Inc. (NYSE:PFE) today announced it will present more than 50 abstracts...
more...
A total of 13 abstracts across seven hard-to-treat cancers highlight the progress of avelumab as a monotherapy and potential novel combination treatment option
New data in metastatic Merkel cell carcinoma and previously treated metastatic urothelial carcinoma, following recent US FDA accelerated approvals
Merck KGaA, Darmstadt, Germany, and Pfizer today announced that 13 avelumab* abstracts across seven challenging tumor types will be featured at the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting held June 2-6, 2017 in Chicago, IL. Key presentations include data for avelumab in first-line metastatic Merkel cell carcinoma (mMCC) and in previously treated metastatic urothelial carcinoma (UC), as well as results from the Phase Ib trial investigating avelumab in combination with the tyrosine kinase inhibitor axitinib, in advanced renal cell carcinoma (RCC).
more...
Pfizer Inc. invites investors and the general public...
more...
Collaboration combines Pfizer’s heritage in Rare Disease, capabilities in gene therapy, and expertise in hemophilia with Sangamo’s deep knowledge in genomic therapies
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and Pfizer Inc. (NYSE: PFE) today announced...
more...
- Second approval for BAVENCIO in less than two months
- Advanced urothelial carcinoma is an aggressive disease with a high rate of recurrence
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer...
more...
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announce that the US Food and Drug Administration (FDA) has granted accelerated approval for BAVENCIO® (avelumab) Injection for a second indication. The full prescribing information for BAVENCIO will be available at www.BAVENCIO.com.
The full prescribing information for BAVENCIO will be available at www.BAVENCIO.com.
more...
App developed by Lupus Research Alliance, Pfizer Inc. and Tata to be tested through non-interventional clinical trial called VALUE
The Lupus Research Alliance, the world’s largest private funder of lupus research, and Pfizer Inc., the global biopharmaceutical company, announced the start of a non-interventional clinical study that will test a custom smartphone app enabling lupus patients to report on their fatigue and other symptoms in real time. Incorporating feedback from people with lupus, the new app will be evaluated through a non-interventional clinical study called VALUE (VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool), scheduled to begin at the end of this month.
more...
Pfizer Inc., the Bill & Melinda Gates Foundation, and the Children’s Investment Fund Foundation reduce the price of the injectable contraceptive
Pfizer Inc., the Bill & Melinda Gates Foundation, and the Children’s Investment Fund Foundation (CIFF) today announced a multi-year extension of their collaboration to further broaden access to Pfizer’s all-in-one injectable contraceptive, Sayana® Press (medroxyprogesterone acetate), for women most in need in some of the world’s poorest countries. Sayana Press will now be available to qualified purchasers at a guaranteed price of US $0.85 per dose, a reduction from the previous price of US $1.00 per dose.
more...
Data Demonstrated Tofacitinib was Effective as Both Induction and Maintenance Therapy in the Treatment of Moderate to Severe Ulcerative Colitis
Pfizer Inc. (NYSE:PFE) announced today that detailed results from the Phase 3 Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) clinical program were published in The New England Journal of Medicine (NEJM).
more...
Please find Pfizer’s press release and associated financial tables at the following hyperlink: Pfizer Reports First-Quarter 2017 Results
more...
Declares 32-Cent Second-Quarter 2017 Dividend
The board of directors of Pfizer Inc. today declared a 32-cent second-quarter 2017 dividend on the company’s common stock, payable June 1, 2017, to shareholders of record at the close of business on May 12, 2017. The second-quarter 2017 cash dividend will be the 314th consecutive quarterly dividend paid by Pfizer.
more...
Pfizer Inc. today announced that its investigational next-generation ALK/ROS1 tyrosine kinase inhibitor, lorlatinib, was granted Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), previously treated with one or more ALK inhibitors.
more...
An Estimated 1 In 18 Patients In Europe Admitted To A Hospital Will Develop A Hospital Acquired Infection Requiring Antibiotic Therapy
Positive results of the...
more...
- ATLAS® Is Designed To Help Physicians Select Appropriate Antibiotics For Their Patients And Responds To The Need For Mobile Resources At The Point Of Care
- ATLAS Can Also Help Inform Global Health Strategies To Mitigate The Threat Of Antimicrobial Resistance (AMR)
Pfizer Inc. today announced the launch of the company’s Antimicrobial Testing Leadership and Surveillance (ATLAS) website, which is designed to provide physicians and the global health community with easy access to critical data on the efficacy of various antibiotic treatments and emerging resistance patterns across more than 60 countries.
more...
Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 9:00 a.m. (Eastern Daylight Time) on Thursday, April 27, 2017.
The international nonprofit organization Population Services International (PSI) and the biopharmaceutical company Pfizer Inc. (NYSE:PFE) today announced Healthy Communities, a US $1 million collaboration to expand access to life-saving hypertension medicines and treatment services in Myanmar and Vietnam.
more...
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for its first-in-class cyclin dependent kinase 4/6 (CDK 4/6) inhibitor, IBRANCE® (palbociclib), based on the results from the confirmatory Phase 3 trial PALOMA-2. The FDA action converts the accelerated approval of IBRANCE to regular approval and broadens the range of anti-hormonal therapy that may be administered with IBRANCE.
more...